Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F19%3A10381949" target="_blank" >RIV/00216208:11110/19:10381949 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/19:10381949 RIV/61989592:15110/19:73596545 RIV/00098892:_____/19:N0000186

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Q4bcojYfzP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Q4bcojYfzP</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/CMAR.S185352" target="_blank" >10.2147/CMAR.S185352</a>

Result language

angličtina

Original language name

Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

Original language description

Background: The principal aim of this report was to study second primary malignant neoplasms (SMNs) in long-term survivors of pancreatic ductal adenocarcinoma (PDAC) with regard to the germline genetic background. Methods: A total of 118 PDAC patients after a curative-intent surgery who were treated between 2006 and 2011 were analyzed. Of the 22 patients surviving for more than five years, 6 went on to develope SMNs. A genetic analysis of 219 hereditary cancer-predisposition and candidate genes was performed by targeted next-generation sequencing (NGS) in germline DNA from 20 of these patients. Results: Of all the radically resected PDAC patients, 6 patients went on to develop SMNs, which accounted for 27% of the long-term survivors. The median time to diagnosis of SMNs, which that included two cases of rectal cancer, and one case each of prostate cancer, malignant melanoma, breast cancer and urinary bladder cancer, was 52.5 months. At the time of analysis, none of these patients had died as a result of PDAC progression. We identified four carriers of germline pathogenic mutations in 20 NGS-analyzed patients. One carrier of the CHEK2 mutation was found among four analyzed patients who developed SMNs. Of the remaining 16 long-term PDAC survivors, three patients (19%) carried germline mutation(s) in the MLH1+ATM, CHEK2, and RAD51D gene, respectively. Conclusion: This retrospective analysis indicates that SMNs in PDAC survivors are an important clinical problem and may be more common than has been acknowledged to be the case. In patients with good performance status, surgical therapy should be considered, as the SMNs often have a favorable prognosis.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancer Management and Research

ISSN

1179-1322

e-ISSN

—

Volume of the periodical

11

Issue of the periodical within the volume

January

Country of publishing house

US - UNITED STATES

Number of pages

11

Pages from-to

599-609

UT code for WoS article

000455427700002

EID of the result in the Scopus database

2-s2.0-85060545014